Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Down 5.90%
As of Thursday, September 24, Corvus Pharmaceuticals, Inc.’s CRVS share price has dipped by 5.90%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Commentary & Analysis
Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Down 5.88%
As of Wednesday, September 23, Corvus Pharmaceuticals, Inc.’s CRVS share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Down 5.31%
As of Wednesday, September 09, Corvus Pharmaceuticals, Inc.’s CRVS share price has dipped by 5.31%, which has investors questioning if this is right time to buy.Michael Rose
Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Up 7.47%
As of Friday, August 21, Corvus Pharmaceuticals, Inc.’s CRVS share price has surged by 7.47%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Up 5.39%
As of Wednesday, August 19, Corvus Pharmaceuticals, Inc.’s CRVS share price has surged by 5.39%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $968.2 | $257.1 | 45% |
|
| Shares Out (Mil) | 92.4 | 54.0 | 60% |
|
| Institutional Ownership | 95.6% | 93.2% | 68% |
|
| Float (Mil) | 72.8 | 41.3 | 55% |
|
| Beta | 0.87 | 0.95 | 52% |
|
| Avg Daily Volume (000s) | 1,390 | 728 | 74% |
|
| Price Change (52-week) |
58.1% | 50.6% | 87% |
|
| Growth | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (20.6%) | (10.1%) | 19% |
|
| EPS (5yr) | (21.3%) | 15.7% | 12 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.3%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.205) | ($0.778) | ($1.068) | |
| Month Ago EPS | ($0.205) | ($0.778) | ($1.068) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.190) | ($0.717) | ($0.947) | |
| Year/Year Chg | 5.7% | 46.2% | 42.9% | |
| Financials | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($54) | ($44) | 16% |
|
| EPS (TTM) | ($0.622) | ($1.600) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($45) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $2 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $957 | $173 | 40% |
|
| Valuation | CRVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.29 | 2.52 | 76% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.2% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (32.9%) | (47.7%) | 16% |
|
| ROE | (35.4%) | (54.9%) | 19% |
|
| Liabilities to Assets | 5.8% | 29.0% | 3% |
|
| F-Score | 4 | 3 | 33% |
|
Corvus Pharmaceuticals, Inc. did not pass any screens on 9/30/2026.
